Granahan Investment Management LLC Increases Stock Holdings in Cellebrite DI Ltd. $CLBT

Granahan Investment Management LLC lifted its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 1,108.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,629,299 shares of the company’s stock after buying an additional 2,411,726 shares during the quarter. Cellebrite DI makes up about 2.0% of Granahan Investment Management LLC’s holdings, making the stock its 12th largest position. Granahan Investment Management LLC’s holdings in Cellebrite DI were worth $48,721,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Invesco Ltd. grew its stake in Cellebrite DI by 58.6% in the 3rd quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock valued at $103,030,000 after acquiring an additional 2,054,644 shares during the last quarter. Voss Capital LP raised its position in Cellebrite DI by 34.0% during the second quarter. Voss Capital LP now owns 5,150,000 shares of the company’s stock worth $82,400,000 after acquiring an additional 1,306,398 shares during the last quarter. Pertento Partners LLP raised its position in Cellebrite DI by 57.8% during the third quarter. Pertento Partners LLP now owns 4,648,215 shares of the company’s stock worth $86,131,000 after acquiring an additional 1,702,574 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of Cellebrite DI by 17.1% in the second quarter. Clal Insurance Enterprises Holdings Ltd now owns 3,913,014 shares of the company’s stock valued at $62,608,000 after purchasing an additional 570,000 shares in the last quarter. Finally, Cooper Creek Partners Management LLC purchased a new stake in shares of Cellebrite DI in the third quarter valued at about $55,999,000. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 29th. Wall Street Zen raised Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday. Finally, Needham & Company LLC lowered their target price on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $22.50.

Cellebrite DI Price Performance

Shares of NASDAQ CLBT opened at $14.44 on Monday. The company has a 50-day simple moving average of $15.27 and a 200-day simple moving average of $16.91. The company has a market cap of $3.60 billion, a PE ratio of 46.58, a price-to-earnings-growth ratio of 2.21 and a beta of 1.30. Cellebrite DI Ltd. has a 12 month low of $11.76 and a 12 month high of $20.86.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.14. The business had revenue of $128.82 million for the quarter, compared to the consensus estimate of $126.07 million. Cellebrite DI had a net margin of 16.47% and a return on equity of 20.43%. The company’s quarterly revenue was up 28.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.10 earnings per share. On average, analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.